Pfizer BioNTech vaccine (Photo: AFP/VNA)

In late September, Pfizer and BioNTech published the results of its clinical trial conducted on 2,268 volunteers, which revealed strong immune response and high safety level in children aged 5-11. The joint venture intends to also seek authorization in other countries. It is studying vaccine efficacy in babies (6 months to 2 years) and children aged 2-5. Preliminary results of trials on these age groups are expected by year end.